Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier

Our group has developed and experimentally validated a strategy to increase antibody penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior work, we demonstrated that 1HE, an anti-trastuzumab single domain antibody that transiently inhibits trastuzumab binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordeau, Brandon M., Abuqayyas, Lubna, Nguyen, Toan D., Chen, Ping, Balthasar, Joseph P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895951/
https://www.ncbi.nlm.nih.gov/pubmed/35250584
http://dx.doi.org/10.3389/fphar.2022.837744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895951/
https://www.ncbi.nlm.nih.gov/pubmed/35250584
http://dx.doi.org/10.3389/fphar.2022.837744

Ejemplares similares